NEUCHATEL, SWITZERLAND--(Marketwired - May 14, 2015) - Masimo (NASDAQ: MASI) announced today a study published in the Journal of the American College of Surgeons found that implementing a multidisciplinary perioperative Enhanced Recovery protocol that included intraoperative fluid management guided by a goal-directed algorithm using Masimo PVI® led to significant reductions in length of stay (LOS), complication rates, and cost for patients undergoing both open and laparoscopic colorectal surgery.1
Masimo's noninvasive PVI is a measure of the dynamic changes in the perfusion index that occur during one or more complete respiratory cycles.
In the retrospective study of the Enhanced Recovery program implemented at the University of Virginia (UVA), Dr. Robert Thiele and colleagues compared the results of 109 patients managed with the program to 98 consecutive patients before the program was implemented. The Enhanced Recovery program included ingestion of a carbohydrate drink two hours prior to surgery, pre-operative multimodal analgesic regimen, goal-directed therapy with Masimo's PVI, intraoperative low-dose spinal morphine, limiting intraoperative opiates, intraoperative infusions of ketamine and lidocaine (continued 48 hours post-operatively), early mobilization, and oral intake post-operatively.
Researchers observed that, as compared to the standard of care group, patients in the Enhanced Recovery program had:
- 2.3 fewer days of hospitalization (4.6 ± 3.6 vs 6.8 ± 4.7, p = 0.0002)
- Reduced mean direct cost ($13,306 vs $20,435, equating to savings of $777,061, p < 0.001)
- Fewer surgical site infections (7.3% vs 20.4%, p = 0.008)
- Less fluid administered (848 mL vs 2,733 mL, p < 0.0001)
- Lower total hospital morphine equivalents (63.7 mg vs 281 mg, p < 0.0001)
- Considerable improvements in patient satisfaction scores
Overall satisfaction increased to the 59th percentile, from 26th
"Felt ready for discharge" increased to the 99th percentile, from 41st
Satisfaction with pain control increased to the 98th percentile, from 43rd
Likelihood that patients would recommend the hospital increased to the 89th percentile, from 32nd
Researchers stated: "The 2.3-day reduction in LOS for the 109 patients on the ER protocol equated to a savings of 261 patient-bed days. Given that the UVA institutional average LOS is 5.5 days, this allowed the Medical Center to admit 47.5 additional patients during this time period as the direct result of the protocol."
The study concluded: "Implementation of an ER protocol led to improved patient satisfaction and significant reduction in LOS, complication rates, and cost for patients undergoing both open and laparoscopic colorectal surgery. These data demonstrate that small investments in the perioperative environment can lead to large returns."
1 Thiele RH, Rea KM, Turrentine FE, Friel CM, Hassinger TE, Goudreau BJ, Umapathi BA, Kron IL, Sawyer RG, Hedrick TL, Standardization of Care: Impact of an Enhanced Recovery Protocol on Length of Stay, Complications, and Direct Costs after Colorectal Surgery, Journal of the American College of Surgeons (2015), doi: 10.1016/j.jamcollsurg.2014.12.042.
Masimo (NASDAQ: MASI) is the global leader in innovative noninvasive monitoring technologies that significantly improve patient care-helping solve "unsolvable" problems. In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. More than 100 independent and objective studies have shown that Masimo SET® outperforms other pulse oximetry technologies, even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced rainbow SET® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC(tm)), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and PVI®, in addition to SpO2, pulse rate, and perfusion index (PI). Additional information about Masimo and its products may be found at www.masimo.com. @Masimoinnovates
This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions of the repeatability of clinical results obtained using Masimo PVI, risks related to our belief that PVI is an easy-to-use and cost-effective measure for assessing whether patients will benefit from fluid administration, risks related to our assumptions that PVI enables personalized and goal-directed fluid therapy, as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws
Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care... by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI are trademarks or registered trademarks of Masimo.
NewsMaker is an Australian Press Release Distribution and Social Media Marketing service founded in 2004. The company today represents over 22,000 brands who seek to share their content with journalists, bloggers and the community.
P: +61 414 69 70 71